Quarterly ResultMay 13, 2026, 04:08 PM
STAAR Surgical Q1 Net Sales $93.5M, up 119.6%; Returns to Profitability
AI Summary
STAAR Surgical reported strong first-quarter 2026 results, with net sales reaching a record $93.5 million, a 119.6% increase year-over-year. The company returned to profitability, posting a net income of $5.2 million and adjusted EBITDA of $24.4 million, a significant turnaround from a net loss in the prior year. Key drivers included a recovery in China with the successful launch of EVO+ ICL and double-digit U.S. net sales growth, alongside improved gross margins and disciplined expense management.
Key Highlights
- Net sales reached a record $93.5 million, up 119.6% year-over-year.
- Reported net income of $5.2 million ($0.10 EPS diluted) vs. $(54.2) million net loss.
- Adjusted EBITDA was $24.4 million ($0.48 per diluted share) vs. $(26.3) million loss.
- Gross margin improved to 73.6% from 65.8% in the prior year quarter.
- Net sales excluding China increased 6.0% to $46.1 million.
- U.S. net sales grew 22% to over $6 million, a quarterly record.
- Surpassed the milestone of 4 million ICLs sold globally.
- Distributor inventory in China normalized, with strong early demand for EVO+ ICL.